Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial

[1]  Bingshu E. Chen,et al.  Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. , 2022, JAMA.

[2]  M. A. Zaki,et al.  The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial , 2022, Scientific Reports.

[3]  Xiufeng Ma,et al.  Metformin and survival of women with breast cancer: A meta‐analysis of randomized controlled trials , 2021, Journal of clinical pharmacy and therapeutics.

[4]  M. Cho,et al.  Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study , 2021, International Journal of Clinical Oncology.

[5]  M. Pistelli,et al.  Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience , 2021, Journal of Oncology.

[6]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[7]  Gowthamarajan Kuppusamy,et al.  Metformin in breast cancer: preclinical and clinical evidence. , 2020, Current problems in cancer.

[8]  Yinan Ji,et al.  Changes in Apparent Diffusion Coefficient as Surrogate Marker for Changes in Ki-67 Index Due to Neoadjuvant Chemotherapy in Patients with Invasive Breast Cancer. , 2019, Academic radiology.

[9]  L. Freedman,et al.  Metformin Treatment and Cancer Risk: Cox Regression Analysis, With Time-Dependent Covariates, of 320,000 Persons With Incident Diabetes Mellitus , 2019, American journal of epidemiology.

[10]  J. Brunet,et al.  The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin , 2019, Front. Oncol..

[11]  A. Segura‐Carretero,et al.  A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study , 2018, Oncotarget.

[12]  G. Pond,et al.  Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[13]  L. Platanias,et al.  Repurposing metformin for cancer treatment: current clinical studies , 2016, Oncotarget.

[14]  Bingshu E. Chen,et al.  Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. , 2015, Journal of the National Cancer Institute.

[15]  T. Hartley,et al.  Metabolic Syndrome Is Associated with Increased Breast Cancer Risk: A Systematic Review with Meta-Analysis , 2014, International journal of breast cancer.

[16]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[17]  S. Cremers,et al.  Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer , 2014, Cancer investigation.

[18]  Jin-hai Tang,et al.  Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer , 2013, Breast Cancer Research and Treatment.

[19]  P. Goodwin,et al.  Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study , 2012, Breast Cancer Research and Treatment.

[20]  A. Luini,et al.  Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Nicholson,et al.  A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  X. Yao,et al.  A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer , 2012, Journal of Cancer.

[23]  A. Tutt,et al.  Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer , 2012, Annals of Surgical Oncology.

[24]  L. Pusztai,et al.  Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial , 2011, Breast Cancer Research and Treatment.

[25]  Peter Donnelly,et al.  Edinburgh Research Explorer Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes , 2022 .

[26]  Massimiliano Cazzaniga,et al.  Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis , 2010, Cancer Prevention Research.

[27]  P. Stattin,et al.  Metabolic Syndrome and Breast Cancer in the Me-Can (Metabolic Syndrome and Cancer) Project , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[28]  Funda Meric-Bernstam,et al.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Grundy,et al.  Ethnic-Specific Criteria for the Metabolic Syndrome , 2006, Diabetes Care.

[31]  Terry L. Smith,et al.  Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.